Genetic variants in DDO and PEX5L in peroxisome‐related pathways predict non‐small cell lung cancer survival

Abstract Peroxisomes play a role in lipid metabolism and regulation of reactive oxygen species, but its role in development and progression of non‐small cell lung cancer (NSCLC) is not well understood. Here, we investigated the associations between 9708 single‐nucleotide polymorphisms (SNPs) in 113 genes in the peroxisome‐related pathways and survival of NSCLC patients from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) and the Harvard Lung Cancer Susceptibility (HLCS) study. In 1185 NSCLC patients from the PLCO trial, we found that 213 SNPs were significantly associated with NSCLC overall survival (OS) ( p ≤ 0.05, Bayesian false discovery probability [BFDP] ≤ 0.80), of which eight SNPs were validated in the HLCS data set. In a multivariate Cox proportional hazards regression model, two independent SNPs (rs9384742 DDO and rs9825224 PEX5L ) were significantly associated with NSCLC survival (hazards ratios [HR] of 1.17 with 95% CI [confidence interval] of 1.06−1.28 and 0.86 with 95% CI of 0.77−0.96, respectively). Patients with one or two protective genotypes had a significantly higher OS (HR: 0.787 [95% CI: 0.620−0.998] and 0.691 [95% CI: 0.543−0.879], respectively). Further expression quantitative trait loci analysis using whole blood and lung tissue showed that the minor allele of rs9384742 DDO was significantly associated with decreased messenger RNA (mRNA) expression levels and that DDO expression was also decreased in NSCLC tumor tissue. Additionally, high PEX5L expression levels were significantly associated with lower survival of NSCLC. Our data suggest that variants in these peroxisome‐related genes may influence gene regulation and are potential predictors of NSCLC OS, once validated by additional studies.